Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia

Adult acute lymphoblastic leukemia (ALL) has a poor overall survival compared with pediatric ALL where cure rates are observed in more than 90% of patients. The recent development of novel monoclonal antibodies targeting CD20, CD19, and CD22 has changed the long-term outcome of this disease, both in...

Descripción completa

Detalles Bibliográficos
Autores principales: Guerra, Veronica A., Jabbour, Elias J., Ravandi, Farhad, Kantarjian, Hagop, Short, Nicholas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535741/
https://www.ncbi.nlm.nih.gov/pubmed/31205644
http://dx.doi.org/10.1177/2040620719849496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535741/
https://www.ncbi.nlm.nih.gov/pubmed/31205644
http://dx.doi.org/10.1177/2040620719849496

Ejemplares similares